Increased fracture risk in Parkinson's disease - An exploration of mechanisms and consequences for fracture prediction with FRAX
Increased fracture risk in Parkinson's disease - An exploration of mechanisms and consequences for fracture prediction with FRAX
The relative contributions of factors such as muscle strength, falls risk and low bone mineral density (BMD) to increased fracture risk in Parkinson's Disease (PD) were examined in an analysis of 5212 community-dwelling women age 75 years or more recruited to a randomised, double-blind, placebo-controlled study of the oral bisphosphonate, clodronate. Similar number of PD and non-PD subjects received treatment. Each participant had measurements of hip and forearm BMD, muscle strength (hand grip strength and maximum isometric quadriceps strength), ability in the sit-to-stand test, and postural stability. Incident radiographic and/or surgically verified fractures, and deaths, were recorded over an average follow-up of 3.8 years. A diagnosis of PD was made if it was self-reported and appropriate medication was recorded at the study entry. 47 of the women (0.9 %) had a diagnosis of PD at baseline. They were of similar age to those without PD, but reported higher disability scores and lower quality of life. While BMD at the forearm and hip regions was lower in PD, this only reached statistical significance at the femoral neck (0.61 ± 0.12 vs 0.65 ± 0.12 g/cm2, p = 0.037). Right hand grip strength was non-significantly lower in PD, but maximum right quadriceps strength was much reduced (96.9 ± 49.3 vs 126.3 ± 59.2 N, p = 0.003). Eleven (23.4 %) of the women with PD sustained 12 fractures, while 609 women (11.8 %) without PD sustained 742 osteoporotic fractures. The risk of osteoporotic fracture associated with PD was 2.24-fold higher in women with PD (Cox-regression HR 2.24, 95 % CI 1.23-4.06) and this remained high when adjusted for death as a competing risk (2.17, 95 % CI 1.17-4.01, p = 0.013). Following adjustment for femoral neck BMD, PD remained a significant predictor of fracture (HR 2.04, 1.12-3.70, p = 0.020). Entering PD as a risk variable using the rheumatoid arthritis input as a surrogate resulted in a reduction in PD as a FRAX-independent risk factor, particularly when BMD was included in FRAX (1.65, 95 % CI), but the relationship between PD and fracture risk appears to remain of clinical significance. The study suggests that PD may be an independent input in future iterations of FRAX, possibly due to non-skeletal components of risk such as reduced lower limb muscle strength. Introducing measures of muscle strength and performance in FRAX could also be considered.
Bone density, FRAX, Fracture risk, Muscle strength, Parkinson's
Schini, M.
8897d6ef-421b-44ad-ac76-7a66429f5c14
Bhatia, P.
1f930aa3-2403-4b39-9538-7ba562517320
Shreef, H.
4a5cbffd-d6d7-47b9-90bc-34d7ed7db18b
Johansson, H.
05aa5476-bcb9-4b97-905e-00f1dfd9d691
Harvey, N C
ce487fb4-d360-4aac-9d17-9466d6cba145
Lorentzon, M
52764ee1-f096-4e53-a266-9d27bd831319
Kanis, J A
55c6bd2c-d653-48de-b4b9-29fe280fb00f
Bandman, O
09968675-7b6a-48f3-a1c5-c8cb60d70b93
McCloskey, E V
e968a69f-27b8-4568-987d-5d8dbbdff3fd
March 2023
Schini, M.
8897d6ef-421b-44ad-ac76-7a66429f5c14
Bhatia, P.
1f930aa3-2403-4b39-9538-7ba562517320
Shreef, H.
4a5cbffd-d6d7-47b9-90bc-34d7ed7db18b
Johansson, H.
05aa5476-bcb9-4b97-905e-00f1dfd9d691
Harvey, N C
ce487fb4-d360-4aac-9d17-9466d6cba145
Lorentzon, M
52764ee1-f096-4e53-a266-9d27bd831319
Kanis, J A
55c6bd2c-d653-48de-b4b9-29fe280fb00f
Bandman, O
09968675-7b6a-48f3-a1c5-c8cb60d70b93
McCloskey, E V
e968a69f-27b8-4568-987d-5d8dbbdff3fd
Schini, M., Bhatia, P., Shreef, H., Johansson, H., Harvey, N C, Lorentzon, M, Kanis, J A, Bandman, O and McCloskey, E V
(2023)
Increased fracture risk in Parkinson's disease - An exploration of mechanisms and consequences for fracture prediction with FRAX.
Bone, 168, [116651].
(doi:10.1016/j.bone.2022.116651).
Abstract
The relative contributions of factors such as muscle strength, falls risk and low bone mineral density (BMD) to increased fracture risk in Parkinson's Disease (PD) were examined in an analysis of 5212 community-dwelling women age 75 years or more recruited to a randomised, double-blind, placebo-controlled study of the oral bisphosphonate, clodronate. Similar number of PD and non-PD subjects received treatment. Each participant had measurements of hip and forearm BMD, muscle strength (hand grip strength and maximum isometric quadriceps strength), ability in the sit-to-stand test, and postural stability. Incident radiographic and/or surgically verified fractures, and deaths, were recorded over an average follow-up of 3.8 years. A diagnosis of PD was made if it was self-reported and appropriate medication was recorded at the study entry. 47 of the women (0.9 %) had a diagnosis of PD at baseline. They were of similar age to those without PD, but reported higher disability scores and lower quality of life. While BMD at the forearm and hip regions was lower in PD, this only reached statistical significance at the femoral neck (0.61 ± 0.12 vs 0.65 ± 0.12 g/cm2, p = 0.037). Right hand grip strength was non-significantly lower in PD, but maximum right quadriceps strength was much reduced (96.9 ± 49.3 vs 126.3 ± 59.2 N, p = 0.003). Eleven (23.4 %) of the women with PD sustained 12 fractures, while 609 women (11.8 %) without PD sustained 742 osteoporotic fractures. The risk of osteoporotic fracture associated with PD was 2.24-fold higher in women with PD (Cox-regression HR 2.24, 95 % CI 1.23-4.06) and this remained high when adjusted for death as a competing risk (2.17, 95 % CI 1.17-4.01, p = 0.013). Following adjustment for femoral neck BMD, PD remained a significant predictor of fracture (HR 2.04, 1.12-3.70, p = 0.020). Entering PD as a risk variable using the rheumatoid arthritis input as a surrogate resulted in a reduction in PD as a FRAX-independent risk factor, particularly when BMD was included in FRAX (1.65, 95 % CI), but the relationship between PD and fracture risk appears to remain of clinical significance. The study suggests that PD may be an independent input in future iterations of FRAX, possibly due to non-skeletal components of risk such as reduced lower limb muscle strength. Introducing measures of muscle strength and performance in FRAX could also be considered.
Text
1-s2.0-S8756328222003283-main
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 20 December 2022
e-pub ahead of print date: 24 December 2022
Published date: March 2023
Additional Information:
Funding Information:
MRC and Leiras Oy funded the study.
Publisher Copyright:
© 2022
Keywords:
Bone density, FRAX, Fracture risk, Muscle strength, Parkinson's
Identifiers
Local EPrints ID: 476613
URI: http://eprints.soton.ac.uk/id/eprint/476613
ISSN: 8756-3282
PURE UUID: bb8515e7-3632-4db9-bb74-206ba3a74383
Catalogue record
Date deposited: 10 May 2023 16:34
Last modified: 17 Mar 2024 02:59
Export record
Altmetrics
Contributors
Author:
M. Schini
Author:
P. Bhatia
Author:
H. Shreef
Author:
H. Johansson
Author:
M Lorentzon
Author:
J A Kanis
Author:
O Bandman
Author:
E V McCloskey
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics